Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Vitamin K Antagonists Versus Low‐molecular‐weight Heparin for the Long Term Treatment of Symptomatic Venous Thromboembolism." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/Vitamin_K_antagonists_versus_low‐molecular‐weight_heparin_for_the_long_term_treatment_of_symptomatic_venous_thromboembolism.
Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/Vitamin_K_antagonists_versus_low‐molecular‐weight_heparin_for_the_long_term_treatment_of_symptomatic_venous_thromboembolism. Accessed February 10, 2025.
Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/Vitamin_K_antagonists_versus_low‐molecular‐weight_heparin_for_the_long_term_treatment_of_symptomatic_venous_thromboembolism
Vitamin K Antagonists Versus Low‐molecular‐weight Heparin for the Long Term Treatment of Symptomatic Venous Thromboembolism [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 February 10]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/Vitamin_K_antagonists_versus_low‐molecular‐weight_heparin_for_the_long_term_treatment_of_symptomatic_venous_thromboembolism.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
ID - 433496
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433496/all/Vitamin_K_antagonists_versus_low‐molecular‐weight_heparin_for_the_long_term_treatment_of_symptomatic_venous_thromboembolism
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -